Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Shi

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
Journal of Cardiac Failure|April 9, 2023
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial)Tor Biering-Sørensen, Mats C Højbjerg Lassen, Amil Shah, et al.
Hypertension (Dallas, Tex. : 1979)|December 28, 2020
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection FractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
JACC. Heart Failure|May 13, 2019
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HFCraig Balmforth, Joanne Simpson, Li Shen, et al.
Blood Pressure|June 24, 2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH studySverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
Circulation. Heart Failure|November 22, 2021
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF TrialAkshay S Desai, Muthiah Vaduganathan, John G Cleland, et al.
European Journal of Heart Failure|February 10, 2021
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysisLuis E Rohde, Muthiah Vaduganathan, Brian L Claggett, et al.
Transplantation|June 4, 2002
T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic miceMarla Weetall, Mary Ellen Digan, Ronald Hugo, et al.
Circulation. Heart Failure|October 26, 2018
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart FailureJames L Januzzi, Milton Packer, Brian Claggett, et al.
Circulation. Heart Failure|October 4, 2014
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696Pardeep S Jhund, Brian L Claggett, Adriaan A Voors, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
Journal of Cardiac Failure|April 9, 2023
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial)Tor Biering-Sørensen, Mats C Højbjerg Lassen, Amil Shah, et al.
Hypertension (Dallas, Tex. : 1979)|December 28, 2020
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection FractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
JACC. Heart Failure|May 13, 2019
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HFCraig Balmforth, Joanne Simpson, Li Shen, et al.
Blood Pressure|June 24, 2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH studySverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
Circulation. Heart Failure|November 22, 2021
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF TrialAkshay S Desai, Muthiah Vaduganathan, John G Cleland, et al.
European Journal of Heart Failure|February 10, 2021
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysisLuis E Rohde, Muthiah Vaduganathan, Brian L Claggett, et al.
Transplantation|June 4, 2002
T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic miceMarla Weetall, Mary Ellen Digan, Ronald Hugo, et al.
Circulation. Heart Failure|October 26, 2018
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart FailureJames L Januzzi, Milton Packer, Brian Claggett, et al.
Circulation. Heart Failure|October 4, 2014
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696Pardeep S Jhund, Brian L Claggett, Adriaan A Voors, et al.
Pageof 7